The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The COSI trial: addition of thiotepa to improve outcomes in patients with AML undergoing alloSCT
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK, discusses the COSI trial (ERN_17-1572), which investigated the addition of thiotepa to improve outcomes in adults with acute myeloid leukemia (AML) and high-risk myelodysplasia undergoing allogeneic stem cell transplantation (alloSCT). Prof. Craddock notes that while the trial did not show a beneficial impact on disease-free survival or overall survival, it did reveal a significant reduction in relapse risk in specific patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
